GE HealthCare’s MIM Software division has received FDA clearance for software to image amyloid plaque in the brains of people with Alzheimer’s disease. The automated MIMneuro programme analyses PET images from any scanner using injectable tracer agents with the aim of providing a standardised metric for one of the main aspects of Alzheimer’s pathology. It…
Category: Alzheimer’s Disease
Leqembi® (lecanemab) authorised for early Alzheimer’s disease in Great Britain
In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* heterozygotes or non-carriers1 Great Britain becomes the first country in Europe to authorise the medicine, which targets an underlying cause of AD1 Authorisation based…
Valiltramiprosate -oral Aβ-targeting therapy for Alzheimer’s disease
American clinical-stage biopharmaceutical company Alzheon has recently presented promising interim results from its Phase II Biomarker Trial (NCT04693520) of its oral, brain-penetrant, amyloid-oligomer inhibitor ALZ-801 (valiltramiprosate) at the American Academy of Neurology 2024 annual meeting. ALZ-801 has the potential to be the first oral Aβ-targeting therapy to be approved in the US and EU in…
Alzheimer’s drug lecanemab rejected by EMA
On 25 July 2024 the European Medicines Agency (EMA) rejected a licence for lecanemab to treat Alzheimer’s disease. The EMA said the benefits did not counterbalance the risk of serious side effects, especially bleeding and swelling in the brain. The MHRA in the UK is still considering whether to grant a licence, and a decision is…
Kisunla (donanemab) gains full FDA approval
Lilly’s Alzheimer’s drug is a challenger for Biogen and Eisai’s Leqembi July 2, 2024: Eli Lilly’s anti-amyloid therapy donanemab for Alzheimer’s disease was rejected for accelerated approval last year, but the FDA has now given it full approval. The FDA has cleared donanemab-abzt, branded as Kisunla, to treat adults with early symptomatic Alzheimer’s disease, including people…
How can scientists model the human brain?
bit.bio launches ioAstrocytes For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. bit.bio, the company coding human cells for novel cures and a pioneer…
Blood tests for diagnosing dementia a step closer for UK
Blood tests for diagnosing dementia are a step closer for UK
Biogen drops Alzheimer’s drug Aduhelm
31 January 2024; Biogen has announced that it will discontinue the development and commercialisation of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study. This decision is not related to any safety or efficacy concerns. A large portion of the resources released resulting from termination of the ADUHELM programme will…
New twice weekly Alzheimer’s disease patch
Alzheimer’s disease treatment can help reduce symptoms and lessen the care burden for patients and their caregivers September 2023: Zeyzelf® twice weekly rivastigmine transdermal patch is for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia and it is the first ever patch to be launched in the UK that does not need daily…
